Comparing 2 hypotheses side-by-side
Synthetic RNA aptamers designed to competitively bind TDP-43's RNA recognition motifs could prevent its interaction with tau and α-synuclein mRNAs, thereby blocking the RNA-mediated cross-seeding mechanism. This approach targets the unique ability of TDP-43 to recruit other proteins through RNA scaffolding.
## Mechanistic Overview Cross-Seeding Prevention Strategy starts from the claim that modulating TARDBP within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "**Molecular Mechanism and Rationale** The cross-seeding prevention strategy targets the pathological interaction between TAR DNA-binding protein 43 (TDP-43), encoded by TARDBP, and classical neurodegenerative disease proteins such as amyloid-beta (Aβ), tau, and alpha-synucle
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
| Dimension | RNA-Binding Competition Therap | Cross-Seeding Prevention Strat |
|---|---|---|
| Mechanistic | 0.500 | 0.720 |
| Evidence | 0.400 | 0.680 |
| Novelty | 0.850 | 0.550 |
| Feasibility | 0.250 | 0.640 |
| Impact | 0.450 | 0.710 |
| Druggability | 0.300 | 0.580 |
| Safety | 0.250 | 0.620 |
| Competition | 0.750 | 0.480 |
| Data | 0.350 | 0.750 |
| Reproducible | 0.300 | 0.590 |
| KG Connect | 0.788 | 0.788 |
No evidence citations yet
No evidence citations yet
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
4 rounds · quality: 0.92
# Novel Therapeutic Hypotheses for RNA Binding Protein Dysregulation in Neurodegeneration ## 1. Stress Granule Phase Separation Modulators **Target:** G3BP1/2, TIA1, TIAR **Mechanism:** Pharmacologic...
# Novel Therapeutic Hypotheses for RNA Binding Protein Dysregulation in Neurodegeneration ## 1. Stress Granule Phase Separation Modulators **Target:** G3BP1/2, TIA1, TIAR **Mechanism:** Pharmacologic...
# Critical Evaluation of RNA Binding Protein Therapeutic Hypotheses ## 1. Stress Granule Phase Separation Modulators **Specific Weaknesses:** - **Temporal specificity problem**: No evidence provided...
# Critical Evaluation of RNA Binding Protein Therapeutic Hypotheses ## 1. Stress Granule Phase Separation Modulators **Specific Weaknesses:** - **Temporal specificity problem**: No evidence provided...
Curated mechanism pathway diagrams from expert analysis
graph TD
A["TDP-43 / TARDBP"] --> B["RNA Processing Functions"]
B --> C["Splicing Regulation"]
B --> D["RNA Transport"]
B --> E["RNA Stability"]
F["Pathological Conditions"] --> G["Cytoplasmic Mislocalization"]
G --> H["Hyperphosphorylation"]
H --> I["TDP-43 Aggregation"]
I --> J["Cross-Seeding with Other Proteins"]
J --> K["ALS/FTD Pathology"]
L["RNA-Binding Competition Therapy"] --> M["Designed RNA Decoys"]
M --> N["Compete for TDP-43 RNA-Binding Domain"]
N --> O["Sequester TDP-43 in Soluble Form"]
O --> P["Prevent Cytoplasmic Aggregation"]
O --> Q["Block Cross-Seeding"]
O --> R["Preserve Some RNA Processing"]
P --> S["Reduced TDP-43 Inclusions"]
Q --> T["Prevented Prion-like Spread"]
R --> U["Maintained Cellular Function"]
S --> V["Neuroprotection in ALS/FTD"]
T --> V
U --> V
style A fill:#264653,stroke:#ffd54f,color:#e0e0e0
style F fill:#4a1942,stroke:#ce93d8,color:#e0e0e0
style L fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
style V fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0
graph TD
A["Cellular Stress Triggers"]
B["TARDBP Gene Expression"]
C["TDP-43 Protein Synthesis"]
D["Nuclear TDP-43 Function"]
E["Cytoplasmic TDP-43 Mislocalization"]
F["TDP-43 Conformational Change"]
G["Beta-Sheet Formation"]
H["Cross-Seeding with Amyloid-beta"]
I["Cross-Seeding with Tau Protein"]
J["Cross-Seeding with Alpha-Synuclein"]
K["Heterotypic Protein Aggregates"]
L["Neuronal Dysfunction"]
M["Synaptic Loss"]
N["Neurodegeneration"]
O["RNA Splicing Modulators"]
P["Protein Disaggregation Therapy"]
A -->|"induces"| B
B -->|"transcribes"| C
C -->|"maintains"| D
A -->|"disrupts"| E
C -->|"mislocalizes"| E
E -->|"triggers"| F
F -->|"promotes"| G
G -->|"initiates"| H
G -->|"initiates"| I
G -->|"initiates"| J
H -->|"forms"| K
I -->|"forms"| K
J -->|"forms"| K
K -->|"causes"| L
L -->|"leads to"| M
M -->|"results in"| N
O -->|"prevents"| E
P -->|"dissolves"| K
classDef mechanism fill:#4fc3f7
classDef pathology fill:#ef5350
classDef therapy fill:#81c784
classDef outcome fill:#ffd54f
classDef genetics fill:#ce93d8
class A,F,G mechanism
class E,H,I,J,K,L pathology
class O,P therapy
class M,N outcome
class B,C,D genetics